A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
🩺 Protocol Summary
This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
Primary Research Facility: Memorial Sloan Kettering Cancer Center (New York, New York)
📋 Preliminary Self-Screener
0 of 3 AnsweredAnswer all 3 basic criteria below to see your preliminary screening result:
📍 Primary Site Map
Site: Memorial Sloan Kettering Cancer Center — New York, New York
📍 All Participating Trial Locations (8 Sites)
Multi-Center TrialThis protocol is enrolling participants across multiple clinical centers:
📄 Print Doctor Discussion Sheet
Preview and print a 1-page summary with 5 tailored questions for your physician.
💰 Clinical Trial Costs & Insurance Coverage
Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.
💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.